Free Trial

Spero Therapeutics (SPRO) Competitors

Spero Therapeutics logo
$2.94 +0.04 (+1.38%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.96 +0.02 (+0.68%)
As of 07/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRO vs. NUVB, DAWN, GHRS, STOK, SANA, MRVI, URGN, AUTL, CDXC, and CDTX

Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry.

Spero Therapeutics vs. Its Competitors

Spero Therapeutics (NASDAQ:SPRO) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Spero Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 70.07%. Nuvation Bio has a consensus price target of $7.17, suggesting a potential upside of 249.59%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spero Therapeutics
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Nuvation Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 5.5% of Spero Therapeutics shares are owned by company insiders. Comparatively, 29.9% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Nuvation Bio had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Nuvation Bio and 0 mentions for Spero Therapeutics. Nuvation Bio's average media sentiment score of 0.83 beat Spero Therapeutics' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Spero Therapeutics Neutral
Nuvation Bio Positive

Spero Therapeutics has a net margin of -156.48% compared to Nuvation Bio's net margin of -5,534.21%. Nuvation Bio's return on equity of -44.14% beat Spero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spero Therapeutics-156.48% -123.50% -58.96%
Nuvation Bio -5,534.21%-44.14%-32.97%

Spero Therapeutics has higher revenue and earnings than Nuvation Bio. Spero Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spero Therapeutics$47.98M3.43-$68.57M-$1.28-2.30
Nuvation Bio$7.87M88.63-$567.94M-$2.35-0.87

Spero Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Summary

Nuvation Bio beats Spero Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRO vs. The Competition

MetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$162.14M$2.88B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-2.3020.8027.0020.10
Price / Sales3.43286.98435.75120.29
Price / CashN/A41.1936.8257.86
Price / Book3.467.487.985.56
Net Income-$68.57M-$55.04M$3.16B$248.40M
7 Day Performance1.38%5.44%3.69%6.04%
1 Month Performance6.52%2.38%2.91%7.69%
1 Year Performance116.97%5.53%34.30%20.97%

Spero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRO
Spero Therapeutics
3.8735 of 5 stars
$2.94
+1.4%
$5.00
+70.1%
+131.5%$162.14M$47.98M-2.30150
NUVB
Nuvation Bio
3.4224 of 5 stars
$1.96
+1.3%
$7.17
+266.6%
-34.3%$656.71M$7.87M-0.8360High Trading Volume
DAWN
Day One Biopharmaceuticals
1.7005 of 5 stars
$6.50
+0.5%
$30.57
+370.3%
-55.3%$655.82M$131.16M-9.1560
GHRS
GH Research
1.5676 of 5 stars
$12.19
-2.0%
$32.00
+162.5%
+31.8%$647.23MN/A-15.4310
STOK
Stoke Therapeutics
3.9883 of 5 stars
$11.35
-2.4%
$23.20
+104.4%
-7.2%$634.96M$190.91M14.37100
SANA
Sana Biotechnology
2.5625 of 5 stars
$2.73
-2.8%
$8.60
+215.0%
-23.4%$633.59MN/A-3.10380Gap Up
MRVI
Maravai LifeSciences
3.7147 of 5 stars
$2.41
-2.4%
$6.64
+175.5%
-62.4%$629.01M$259.18M-2.11610
URGN
Urogen Pharma
4.5398 of 5 stars
$13.70
+1.6%
$32.86
+139.8%
-14.8%$621.99M$90.40M-4.31200Analyst Forecast
AUTL
Autolus Therapeutics
2.1262 of 5 stars
$2.28
-1.3%
$9.32
+308.8%
-36.7%$614.79M$10.12M-2.59330
CDXC
ChromaDex
3.1895 of 5 stars
N/A$9.03
+∞
N/A$611.50M$99.60M787.29120
CDTX
Cidara Therapeutics
4.2094 of 5 stars
$48.71
-1.5%
$57.14
+17.3%
+328.3%$603.74M$1.27M-1.6590Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:SPRO) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners